Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 156 recommendations for 80 medicines and 3 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
6.2. Antibacterials
  1. Amikacin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)
    Second choice
    co-prescribed with cloxacillin Sepsis without septic shock
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  2. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    Indications
    First choice
    Chronic obstructive pulmonary disease with acute exacerbation co-prescribed with gentamicin Sepsis without septic shock
    Other indications
    Bacterial infection of unspecified site Infectious cystitis
  3. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
    • Oral > Solid: 500 mg + 125 mg tablet
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    Indications
    First choice
    Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation
    Other indications
    Bacterial infection of unspecified site
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  4. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
    • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritonitis (severe) co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
  5. Azithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
    Indications
    First choice
    co-prescribed with ceftriaxone Gonococcal infection
    Second choice
    co-prescribed with cefixime Gonococcal infection
  6. Aztreonam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified bacterial diseases
  7. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  8. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
    Indications
    First choice
    Syphilis Congenital syphilis [children]
    Other indications
    Bacterial infection of unspecified site
  9. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
    Indications
    First choice
    Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
  10. Capreomycin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  11. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    Indications
    Second choice
    Chronic obstructive pulmonary disease with acute exacerbation
    Other indications
    Bacterial infection of unspecified site
  12. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
    Other indications
    Surgical site infection
  13. Cefepime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
    Indications
    Other specified bacterial diseases
  14. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection
  15. Cefotaxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
    Indications
    Bacterial infection of unspecified site
  16. Ceftaroline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
    Indications
    Other specified bacterial diseases
  17. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    co-prescribed with vancomycin Endophthalmitis
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic
  18. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  19. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  20. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    co-prescribed with metronidazole Necrotising fasciitis
    Other indications
    Bacterial infection of unspecified site
  21. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  22. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Bacterial infection of unspecified site
  23. Ciprofloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
    • Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Indications
    First choice
    Inflammatory and other diseases of prostate (mild to moderate)
    Other indications
    Bacterial infection of unspecified site
  24. Clindamycin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    Indications
    Bacterial infection of unspecified site
  25. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Leprosy
  26. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
    Indications
    Bacterial infection of unspecified site
  27. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
    Indications
    Other specified bacterial diseases
  28. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  29. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  30. Daptomycin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  31. Delafloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
    • Oral > Solid: 450 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  32. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  33. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Solid: 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
    Indications
    First choice
    Chlamydia trachomatis
    Second choice
    Chronic obstructive pulmonary disease with acute exacerbation
    Other indications
    Bacterial infection of unspecified site
  34. Eravacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg lyophilized powder for injection
    Indications
    Carbapenem resistant Enterobacterales
  35. Erythromycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
    • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
    • Oral > Solid: 250 mg (as stearate or ethylsuccinate)
    Indications
    Bacterial infection of unspecified site
  36. Ethambutol General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
    • Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)
    Indications
    Other specified tuberculosis Tuberculosis
  37. Ethambutol + isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  38. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  39. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  40. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculous meningitis
  41. Fifth generation cephalosporins General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  42. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  43. Fourth generation cephalosporins General information
    Section
    Watch group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  44. Gatifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  45. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Sepsis without septic shock co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shock co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Other specified prophylactic measures Gonococcal infection
    Other indications
    Bacterial infection of unspecified site
  46. Imipenem + cilastatin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
    Indications
    Second choice
    Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
  47. Imipenem + cilastatin + relebactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa
  48. Isoniazid General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 100 mg per mL
    • Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet
    Indications
    Other specified tuberculosis Tuberculosis
  49. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)
    Indications
    Tuberculosis
  50. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
    Tuberculosis
  51. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  52. Kanamycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  53. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  54. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    Indications
    Other specified bacterial diseases
    Section
    Antituberculosis medicines
    • Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  55. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  56. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  57. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    Indications
    First choice
    co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe)
    Second choice
    co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate)
    Other indications
    Bacterial infection of unspecified site
  58. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
    • Oral > Solid: 400 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculosis
  59. Ofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  60. Omadacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
    • Oral > Solid: 300 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  61. Oxazolindinones General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  62. P-aminosalicylate sodium General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  63. P-aminosalicylic acid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 4 g granules in sachet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  64. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    First choice
    Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
    Other indications
    Bacterial infection of unspecified site
  65. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    Peritoneal abscess (severe) Neutropenia (high-risk) Peritonitis (severe) Other specified pneumonia (Hospital-acquired pneumonia)
  66. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  67. Polymyxins General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  68. Pretomanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  69. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    First choice
    Congenital syphilis [children]
    Second choice
    Syphilis
  70. Protionamide General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis
  71. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg
    Indications
    Tuberculosis
  72. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  73. Rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    • Parenteral > General injections > IV: 600 mg in vial powder for injection
    Indications
    Tuberculosis Other specified tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  74. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg tablet; 300 mg tablet
    Indications
    Tuberculosis Latent tuberculosis
  75. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Gonococcal infection
    Other indications
    Bacterial infection of unspecified site
  76. Streptomycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  77. Sulfamethoxazole + trimethoprim General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    Indications
    Bacterial infection of unspecified site
  78. Terizidone General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis
  79. Tetracycline General information
    Section
    Access group antibiotics
    • Oral > Solid: 250 mg (hydrochloride)
    Indications
    Bacterial infection of unspecified site
  80. Tigecycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  81. Trimethoprim General information
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    First choice
    Infectious cystitis
  82. Vancomycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    Indications
    First choice
    co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis
    Other indications
    Methicillin resistant Staphylococcus aureus